Nuveen
RCKT icon

Nuveen’s Rocket Pharmaceuticals RCKT Stock Holding History

Nuveen’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$683K Sell
199,794
-2,928,959
-94% -$9.74M ﹤0.01% 3127
2026
Q1 		$11.2M Buy
3,128,753
+2,970,741
+1,880% +$11.8M ﹤0.01% 1486
2025
Q4 		$555K Hold
158,012
– – ﹤0.01% 2833
2025
Q3 		$515K Sell
158,012
-480,503
-75% -$1.51M ﹤0.01% 2876
2025
Q2 		$1.56M Buy
638,515
+460,222
+258% +$2.33M ﹤0.01% 2409
2025
Q1 		$1.19M Buy
178,293
+10,577
+6% +$104K ﹤0.01% 2562
2024
Q4 		$2.11M Hold
167,716
– – ﹤0.01% 2363
2024
Q3 		$3.1M Hold
167,716
– – ﹤0.01% 2218
2024
Q2 		$3.61M Buy
167,716
+7,680
+5% +$176K ﹤0.01% 2102
2024
Q1 		$4.31M Sell
160,036
-3,383
-2% -$96.1K ﹤0.01% 2066
2023
Q4 		$4.9M Buy
163,419
+11,738
+8% +$259K ﹤0.01% 1987
2023
Q3 		$3.11M Sell
151,681
-2,764
-2% -$50.2K ﹤0.01% 2107
2023
Q2 		$3.07M Buy
154,445
+1,222
+0.8% +$24.7K ﹤0.01% 2150
2023
Q1 		$2.62M Sell
153,223
-350,498
-70% -$6.86M ﹤0.01% 2227
2022
Q4 		$9.86M Buy
503,721
+271,332
+117% +$5M ﹤0.01% 1499
2022
Q3 		$3.71M Sell
232,389
-127,151
-35% -$1.98M ﹤0.01% 2066
2022
Q2 		$4.95M Buy
359,540
+73,491
+26% +$876K ﹤0.01% 1948
2022
Q1 		$4.33M Buy
286,049
+134,610
+89% +$2.33M ﹤0.01% 2140
2021
Q4 		$3.31M Sell
151,439
-18,139
-11% -$495K ﹤0.01% 2325
2021
Q3 		$5.07M Sell
169,578
-104,351
-38% -$3.8M ﹤0.01% 2201
2021
Q2 		$12.1M Buy
273,929
+58,375
+27% +$2.54M ﹤0.01% 1733
2021
Q1 		$9.56M Buy
215,554
+77,714
+56% +$4.27M ﹤0.01% 1827
2020
Q4 		$4.42M Sell
137,840
-143,124
-51% -$5.22M ﹤0.01% 2139
2020
Q3 		$6.42M Sell
280,964
-84,567
-23% -$2.08M ﹤0.01% 1790
2020
Q2 		$7.65M Buy
365,531
+66,754
+22% +$1.2M ﹤0.01% 1670
2020
Q1 		$4.17M Buy
298,777
+188,830
+172% +$3.74M ﹤0.01% 1817
2019
Q4 		$2.5M Buy
109,947
+6,129
+6% +$102K ﹤0.01% 2331
2019
Q3 		$1.21M Sell
103,818
-4,874
-4% -$60.5K ﹤0.01% 2616
2019
Q2 		$1.63M Buy
+108,692
New +$1.9M ﹤0.01% 2529

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Nuveen's RCKT Position: Q2 2026 in Review

Nuveen reduced its Rocket Pharmaceuticals (RCKT) stake by 94% in Q2 2026, selling an estimated $9.74M and leaving 199,794 shares worth $683K. The position accounts for ﹤0.01% of the portfolio, ranked #3127.

Nuveen first reported a position in RCKT in Q2 2019 and has held it in 29 quarters since. The position peaked at $12.1M in Q2 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Nuveen held 199,794 shares of Rocket Pharmaceuticals worth $683K as of Q2 2026.
  • Nuveen sold 2,928,959 Rocket Pharmaceuticals shares in Q2 2026, an estimated $9.74M.
  • Rocket Pharmaceuticals made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3127 holding.
  • Nuveen first reported a position in Rocket Pharmaceuticals in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Rocket Pharmaceuticals position peaked at $12.1M in Q2 2021.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.